Samsung Biologics, a contract development and manufacturing organization (CDMO), reported that it plans to have its new fifth plant operational by April 2025. On June 1, the company fully completed its latest and the world’s largest biomanufacturing plant, Plant 4.

As the first facility of Samsung Biologics’ second Bio Campus at its headquarters in Songdo, South Korea, Plant 5 is expected to have the shortest construction timeline, made possible by the company’s standardized design and experience acquired through the construction of its existing four plants. The new plant will add a capacity of 180,000 liters, and upon completion, Samsung Biologics will maintain the world’s largest biomanufacturing capacity at 784,000 liters.

Plant 5’s key features also include seamless process integration and optimization as well as advanced automation to deliver high productivity and quality throughout its operations. The new plant will also incorporate sustainable systems to support achieving net zero greenhouse gas emissions by 2050 or earlier.

All facilities will be connected to maximize output and efficiency with automated logistics and will incorporate technologies with fully digitalized systems to offer seamless client communication. Upon the completion of Bio Campus II, Samsung Biologics will hold a total capacity of 1.324 million liters.

“Over a decade ago, we committed to bringing innovative solutions to our partners, and we’ve successfully delivered on that commitment with each new plant. Now building on this foundation, Plant 5 will leverage our unparalleled experience and expertise to deliver long-term success for our clients,” said John Rim, President, and CEO of Samsung Biologics. “By expediting our capacity expansion and providing fully integrated services, we hope to close the gap between the demand and supply of life-saving biomedicines.”